Upregulation of AXL and its major ligand GAS6, has been reported in a wide variety of cancer cell lines as well as in cancer specimens from patients with breast cancer, acute leukemia, colorectal cancer, lung cancer, melanoma, ovarian cancer, or prostate cancer, among others [11]. This evidence concerns the gene GAS6 and breast carcinoma.